Ivermectin is an antiparasitic drug that has been touted for the use of Covid 19 in people who aren’t sick enough to warrant hospitalization (see January 6th blogpost). Unfortunately, this study does not show a benefit to taking it. Here is a summary from Journal Watch followed by a link to the original article.
Ivermectin & mild illness: The antiparasitic ivermectin does not seem to improve outcomes in mild COVID-19, according to a randomized, single-center trial in JAMA. Previous research has suggested a potential effect against SARS-CoV-2. In the new trial, roughly 400 adults in Colombia with mild COVID-19 who were within 7 days of symptom onset were randomized to receive ivermectin oral solution or placebo daily for 5 days. Patients could be at home or hospitalized without needing high-flow oxygen or mechanical ventilation. The primary outcome — time to resolution of symptoms — did not differ significantly between the groups (median: 10 days with ivermectin, 12 with placebo). By day 21, symptoms had resolved in roughly 80% of patients in each group. Some 7.5% of patients in the ivermectin group and 2.5% in the placebo group discontinued treatment because of adverse events.